Phase 3 Stroke Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 to 90 years old
- People who have had an acute ischemic stroke (a stroke caused by a blocked blood vessel in the brain) with a significant or complete blockage in one of several specific brain arteries, confirmed by imaging
- People whose brain scans show that some brain tissue may still be saved (salvageable tissue)
- People whose stroke symptoms score at least 5 points on a standard medical stroke severity scale called the NIHSS (a higher score means more severe symptoms)
Who may not be able to join:
- People whose brain scans before the study show a large area of already-damaged brain tissue, blockages in more than one brain artery region, significant brain swelling, or signs of bleeding in or around the brain, a brain tumour (with some exceptions), or an abnormal tangle of blood vessels in the brain
- People whose scans or medical history suggest the brain artery blockage has been there for a long time rather than happening recently
- People with a current or past history of serious bleeding problems, or conditions that the study doctor considers to carry a significant risk of major bleeding
- People with very high blood pressure that cannot be brought under control with medication (confirm with trial site for specific thresholds)
- People with known blood clotting disorders or abnormal blood test results related to clotting (confirm with trial site for specific values)
- People who have recently had a major injury, surgery, or invasive medical procedure
- People with a pre-existing medical, neurological, or psychiatric condition that could interfere with how the study measures outcomes
- People with a blood sugar level that is either very high or very low before treatment, unless it is corrected before the study treatment is given — people whose blood sugar returns to a normal range may still be considered, at the study doctor's discretion
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Senior Director, Clinical Operations, Corxel Pharmaceuticals
Phone: 201-268-3723
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Efficacy: Proportion of participants with no or minimal symptoms (mRS score 0-1) at 90 days; Safety: Incidence of symptomatic intracranial hemorrhage within 36 hours post-randomization
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.